RAPP — Rapport Therapeutics Balance Sheet
0.000.00%
- $1.16bn
- $648.48m
- 40
- 33
- 85
- 52
Annual balance sheet for Rapport Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Cash and Equivalents | |||
| Short Term Investments | |||
| Cash and Short Term Investments | 31.2 | 147 | 305 |
| Prepaid Expenses | |||
| Total Other Current Assets | |||
| Total Current Assets | 31.3 | 151 | 310 |
| Gross Property, Plant And Equipment | |||
| Accumulated Depreciation | |||
| Net Property, Plant And Equipment | 0.335 | 4 | 4.97 |
| Other Long Term Assets | |||
| Total Assets | 31.6 | 155 | 315 |
| Accounts Payable | |||
| Accrued Expenses | |||
| Notes Payable / Short Term Debt | |||
| Total Other Current Liabilities | |||
| Total Current Liabilities | 1.66 | 8.8 | 8.77 |
| Long Term Debt | |||
| Total Long Term Debt | |||
| Total Debt | |||
| Total Other Liabilities | |||
| Total Liabilities | 12.1 | 14.5 | 9.51 |
| Non Redeemable Preferred Stock | |||
| Common Stock | |||
| Additional Paid In Capital | |||
| Retained Earnings (Accumulated Deficit) | |||
| Other Equity | |||
| Total Equity | 19.5 | 141 | 305 |
| Total Liabilities & Shareholders' Equity | 31.6 | 155 | 315 |
| Total Common Shares Outstanding |